// App-Quantinova.ai

BSH19‐PO‐105 : Real world experience of Daratumumab monotherapy as fourth line therapy in relapsed/refractory myeloma

Researchers

Presenter

  • J.B. Taube

Principal Investigators

  • S. Chavda

  • R. Popat

  • X. Papanikolaou

  • S. Cheesman

  • S. Sachchithanantham

  • S. Mahmood

  • A. Mehta

  • S. D'Sa

  • C. Kyrioakou

  • A. Wechalekar

  • K. Yong

  • N. Rabin

Medical Centers

  • Department of Rheumatology, University College London, London, UK

  • National Amyloidosis Cntr, Royal Free Hosp, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Tumor protein p53

Drug/Treatment

  • daratumumab Intravenous

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved